Sanvar IR “approvable”
Executive Summary
H3 Pharma's somatostatin analog Sanvar IR is "approvable" at FDA for the acute treatment of esophageal variceal bleeding. FDA issued the "approvable" letter for the vapreotide NDA Dec. 21. The agent had an estimated action date of Dec. 27. Sanvar IR is designated as an orphan drug...